NVIDIA Corporation’s ( NVDA ) Q4 '25 earnings were quite superb. Revenue was up 73% to $68.1 billion. Gross margins also expanded 200 basis points to 75% and did not indicate any pricing pressure. And operating expenses expanded atAs an investor I focus on small and midcap names with asymmetric upsides. In the beginning of my professional career I was handed the Industrials and chemicals sector on the sell side. More recently I worked as the Manager of Finance & Technology at a Canadian charity in Vancouver ...

分组1 - NVIDIA Corporation's Q4 '25 earnings showed a remarkable revenue increase of 73% to $68.1 billion [1] - Gross margins expanded by 200 basis points to 75%, indicating no pricing pressure [1] - Operating expenses also increased, although specific figures were not provided [1]

Market Analysis by covering: AEX, Dow Jones Industrial Average, Eli Lilly and Company, PGS ASA. Read 's Market Analysis on Investing.com ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Neurizon Therapeutics has initiated dosing of its lead candidate NUZ-001 in the HEALEY ALS Platform Trial, marking a significant milestone in the development of treatments for amyotrophic lateral sclerosis (ALS) [1][2] Company Overview - Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on advancing innovative treatments for neurodegenerative diseases, particularly ALS [1] - The company aims to accelerate access to effective ALS treatments while exploring broader applications for NUZ-001 in neurodegenerative disorders [1] Clinical Trial Details - The HEALEY ALS Platform Trial is a multicenter, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial designed to evaluate multiple investigational drugs concurrently [1][2] - Approximately 160 participants with ALS will be enrolled in a 36-week randomized, double-blind, placebo-controlled trial, with a primary objective to assess the efficacy of NUZ-001 compared to placebo [1] - The trial is conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham, in collaboration with the Network of Excellence for ALS (NEALS) [1] Study Design and Objectives - Regimen I of the trial includes a randomized controlled treatment phase followed by an active treatment extension phase, both lasting 36 weeks [1] - Participants will receive either daily NUZ-001 at a dose of 10 mg/kg or a placebo at a 3:1 ratio [1] - Secondary objectives include additional measures of disease progression and safety [1] Infrastructure and Collaboration - The HEALEY ALS Platform Trial leverages shared infrastructure across over 70 clinical sites, enhancing trial efficiency and data generation [1][2] - The trial's design allows for streamlined start-up and enrollment processes, facilitating faster results and ongoing engagement with regulatory authorities, including the FDA [1] Leadership Commentary - The Principal Investigator, Professor Merit Cudkowicz, emphasized the significance of the trial's initiation and the collaboration with Neurizon [1] - Neurizon's Managing Director, Dr. Michael Thurn, highlighted the trial as a registrational study aimed at generating clinical evidence for potential regulatory submissions [1]

The pilot is being implemented by the Puducherry government, the RBI, the Public Financial Management System (PFMS) and Canara BankCurrently being piloted in Puducherry, the Centre plans to expand the initiative to three to four states and UTs, including Chandigarh and Dadra and Nagar Haveli, “soon”Beneficiaries will get digital coupons in their CBDC wallets, which can then be used to redeem the entitled quantity of foodgrains at merchant outletsThe Centre yesterday rolled out a central bank digital currenc ...

7,472,300+$15.12+7.90%$206.62[GoDaddy][GDDY]• Vol: 3,849,474+$5.67+7.17%$84.79## Top Losing Stocks[Universal Health Services][UHS]• Vol: 1,118,971-$25.4811.04%$205.25[Corning][GLW]• Vol: 14,527,219-$10.706.67%$149.74[Albemarle][ALB]• Vol: 1,735,540-$11.415.82%$184.47[First Solar] [FSLR]• Vol: 3,751,568-$12.115.76%$198.01[NVIDIA][NVDA]• Vol: Overall Grade: B+ - Synopsys beat on both revenue and earnings, with the Ansys…]## HP Inc. Earnings Preview: What Wall Street Is Watching[Joel South | Feb 24, 2026 at 1: ...

That release could not be found. ...

The archived webcast will be available for one year following the event. Additionally, an investor slide presentation will be available beginning Monday, March 2, 2026, at www.ubsi-inc.com. United Bankshares, Inc. is a financial services company with consolidated assets of approximately $34 billion as of December 31, 2025. It is the parent company of United Bank, which comprises over 240 offices located across Washington, D.C., Virginia, West Virginia, Maryland, North Carolina, South Carolina, Ohio, Pennsyl ...

"By prioritizing efficiencies and thoughtful change, we can continue to focus to what matters most—our people and the customers and communities we serve.†- Beth Ryan, Vice President Senior Retail Operations Manager Share SANTA ROSA, Calif.--(BUSINESS WIRE)--Exchange Bank (OTC: EXSR) is pleased to announce the promotion of Beth Ryan from Vice President, Community Engagement Officer to Vice President Senior Retail Operations Manager, reflecting her more than three decades of leadership, service, and deep comm ...